The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
I know I keep going on about it but look at Imutex - it has very little money and is going nowhere atm (Orph rightly refuse to give it more cash) so something needs to be done (at a time where infectious disease is massively high profile) therefore I don’t think our divi from Imutex is too far away (same for Prep)
He did say shareholders will not be disappointed so who knows - I think a Prep sale has also a decent possibility
Interesting interview - so my take is
- Prep will be sorted in next few months
- imutex made progress but still frustrating
- Focus on Poolbeg for next few months then do DIM
- More contracts in negotiations and possible CEO
- Cash dividend (and buy backs) unlikely
All positive - just wish the share price would see it that way
STT - you ask why wouldn't shareholders wait to buy DIM when it floats - the simple answer is you will miss out on your free shares. I am not convinced there will be another lock in when DIM is floated
This is a Company that is crumbling according to JB
JB - what evidence do you have to back up your systems to that the Open Orphan Company is crumbling???
Was it a big announcement that couldn’t be finalised therefore the whole thing was cancelled??
Mr Beam is quiet today - I guess a reversal doesn’t fit in with his narrative
Just being looking again at the Imutex situation - they have insufficient funds to take FluV to Phase 3 therefore something needs to be done - how about a Nasdaq float with a shares or cash offer to Orph shareholders (no lock in as you can take the cash if you want)
If we assume (very conservatively) that the remaining 3 spin outs are worth 10p a share then our current enterprise value of £110 m less £15 cash and £66 million for spin outs is less than £30m . How is that realistic for a Company with no debt increasing turnover over 100% this year and a further 25%+ next with a decent EBITDA profit - compared that with some of the real dogs out there
Seen - I doubt CF believes that the recent contract win was the ‘watch this space before Christmas we won’t let our long suffering shareholder down’ news. He only has to look back at the large contract wins at the end of Aug and Sept to see they had no effect
Hi Matt - do you have an email address for CF or is it just through Investor Relations??
I think Earache has moved to Cheshire and is even more wide of the negative mark than normal
Why can’t CF or our Broker place the shares of the supposed 2 big sellers (or the Company could mop up some of the excess liquidity) - very frustrating but the sellers will run out - eventually!!!
Potential acquisition target??
Has anybody received replies from investor relations?? Two emails from me have been ignored
Looks like the Buys and Sells are roughly the same and the SP is up a fraction - doesn't seem like a big problem to me - I think you are scratching around for problems
OK - maybe you said down to the last 2 or 3 - are they selling???
I thought you said the Institutions are all out????
I have the same feeling Ryan - should start hotting up very shortly and with most of the institutions out (except the couple of loyal ones) I am hoping for a steady rise from here